TABLE 2.

Determinants for the first switch to a second biological for RD patients

	No. cases N = 171	No. controls N = 627	OR (univariate) 95% CI	OR (multivariate) 95% CI
Median (IQR)age at index date	47.4 (29.5)	48.2 (26.3)	0.99 (0.98–1.00)	—
Gender
Males	61 (35.7%)	241 (38.4%)	Ref
Females	110 (64.3%)	386 (61.6%)	0.88 (0.81–1.60)	—
TNFα dose escalation
No	168 (98.2%)	626 (99.8%)	Ref
Yes	3 (1.8%)	1 (0.2%)	12 (1.25–115.4)*	13.78 (1.40–135.0)
Initiation/dose escalation immunomodulator
No	143 (83.6%)	547 (87.2%)	Ref
Yes	28 (16.4%)	80 (12.8%)	1.43 (0.85–2.42)	—
High‐dose corticosteroid
No	166 (97.1%)	621 (99.0%)	Ref
Yes	5 (2.9%)	6 (1.0%)	3.24 (0.99–10.65)*	3.62 (1.10–12.15)
Serum concentration measurement
No	170 (99.4%)	627 (100%)
Yes	1 (0.6%)	0 (0%)	NA	—

^* p‐value <.1.